Adam R, Aloia T, Krissat J, et al: Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg 244:897–908, 2006.
Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med 366:520–529, 2012.
Baselga J, Cortés K, Kim S-B, et al. Pertuzumab plus trastuzumab(Drug information on trastuzumab) plus docetaxel(Drug information on docetaxel) for metastatic breast cancer. N Engl J Med 366:109–119, 2012.
Bergh J, Jönsson PE, Lidbrink E, et al: First results from FACT—an open-label, randomized phase III study investigating loading dose of fulvestrant combined with anastrozole(Drug information on anastrozole) versus anastrozole at first relapse in hormone receptor positive breast cancer. Presented at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, TX. Abstract 23.
Blackwell KL, Burstein HJ, Storniolo AM, et al: Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2–positive metastatic breast cancer: Final results from the EGF104900 study. J Clin Oncol 30:2585–2592, 2012.
Brufsky A, Bondarenko IN, Smirnov V, et al: RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab(Drug information on bevacizumab) in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 69(suppl):42, 2009.
Brufsky AA, Rivera RR, Hurvitz SA, et al: Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 28(15s):1021, 2010.
Chia S, Gradishar W, Mauriac L, et al: Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane(Drug information on exemestane) after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26:1664–1670, 2008.
Cortes J, O'Shaughnessy J, Loesch D, et al: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet 377(9769):914–923, 2011.
Dalenc F, Campone P, Hupperets R, et al: Everolimus in combination with weekly paclitaxel(Drug information on paclitaxel) and trastuzumab in patients (pts) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial. J Clin Oncol 28(15S):1013, 2010.
Di Leo A, Jerusalem G, Petruzelka L, et al: Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer. J Clin Oncol 28:4594–4600, 2010.
Formenti SC, Dunnington G, Uzieli B, et al: Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int J Radiat Oncol Biol Phys 39:1059–1068, 1997.
Garcia-Mata J, Garcia-Palomo A, Calvo L, et al: Phase II study of dose-dense doxorubicin and docetaxel as neoadjunvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer. Clin Transl Oncol 10:739–744, 2008.
Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine(Drug information on capecitabine) for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743, 2006.
Geyer CE, Martin A, Newstat B, et al: Lapatinb plus capecitabine in HER2+ advanced breast cancer: Genomic and updated effiacy data. J Clin Oncol 25(18s):1035, 2007.
Le Scodan R, Stevens D, Brain E, et al: Breast cancer with synchronous metastases: Survival impact of exclusive logoregional radiotherapy. J Clin Oncol 27:1375–1381, 2009.
Miles D, Chan A, Romeiu G, et al: A randomized, double-blind study of bevacizumab in combination with docetaxel as first-line treatment of patients with HER2-negative locally recurrent or metastatic breast cancer: Efficacy and safety. J Clin Oncol 26(suppl); abstract LBA1011, 2008.
Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676, 2007.
O'Shaughnessy JA, Brufsky A: RiBBON 1 and RiBBON 2: Phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer. Clin Breast Cancer 8:370–373, 2008.
O'Shaughnessy J, Miles D, Gray RJ, et al: A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 28(15s): abstract 1005, 2010.
O'Shaughnessy J, Schwartzberg LS, Danso MA, et al: A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine(Drug information on gemcitabine)/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 29(suppl): abstract 1007, 2011.
Perez EA, Lerzo G, Pivot X, et al: Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407–3414, 2007.
Sledge G, Miller K, Moisa C, et al: Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. J Clin Oncol 25(18s):1013, 2007.
Stopeck A, Lipton A, Brody JJ, et al: Denosumab compared with zoledronic acid(Drug information on zoledronic acid) for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 28:5132–5139, 2010.
Thomas ES, Gomez HL, Li RK, et al: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210–5217, 2007.
Twelves C, Loesch D, Blum JL, et al: A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 28:(18s): abstract CRA1004, 2010.